Results 221 to 230 of about 25,411 (262)

Mineralocorticoid receptor antagonists

Current Hypertension Reports, 2007
With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of
Parthasarathy, Hari Krishnan, MacDonald, Thomas M.   +1 more
openaire   +3 more sources

Mineralocorticoid receptor antagonists

2022
Abstract This chapter studies the use of aldosterone antagonists, also known as mineralocorticoid receptor antagonists (MRAs), in chronic heart failure (CHF). Overall, the results for aldosterone blockade in CHF due to left ventricular systolic dysfunction—now called heart failure with reduced ejection fraction (HFrEF)—have been very ...
S. Rekhraj, Ben. R. Szwejkowski, Allan D. Struthers   +2 more
openaire   +1 more source

3,3-Bisaryloxindoles as mineralocorticoid receptor antagonists

Bioorganic & Medicinal Chemistry Letters, 2005
Syntheses and SAR studies of 3,3-bisaryloxindole analogues provided potent mineralocorticoid receptor (MR) antagonists that were selective over other steroid nuclear hormone receptors.
David A, Neel, Matthew L, Brown, Peter A, Lander, Timothy A, Grese, Jean M, Defauw, Robert A, Doti, Todd, Fields, Sally Ann, Kelley, Stephon, Smith, Karen M, Zimmerman, Mitchell I, Steinberg, Prabhakar K, Jadhav   +11 more
openaire   +3 more sources

Mineralocorticoid Receptor Antagonists in Primary Aldosteronism

Current Pharmaceutical Design, 2019
Background:Primary aldosteronism is the most common causes of secondary hypertension. Patients suffering from this clinical syndrome have an increased cardiovascular risk and target organ damage. Mineralocorticoid receptor antagonists are the optimal pharmaceutical option for the management of such patients.Objectives:The study aimed to assess the ...
Konstantinos, Stavropoulos, Christodoulos, Papadopoulos, Konstantinos, Koutsampasopoulos, Georgios, Lales, Christos, Mitas, Michael, Doumas   +5 more
openaire   +2 more sources

Nonsteroidal antagonists of the mineralocorticoid receptor

Current Opinion in Nephrology and Hypertension, 2015
The broad clinical use of steroidal mineralocorticoid receptor antagonists (MRAs) is limited by the potential risk of inducing hyperkalemia when given on top of renin-angiotensin system blockade. Drug discovery campaigns have been launched aiming for the identification of nonsteroidal MRAs with an improved safety profile.
Peter, Kolkhof, Christina, Nowack, Frank, Eitner   +2 more
openaire   +2 more sources

Non-steroidal mineralocorticoid receptor antagonists

Expert Opinion on Therapeutic Patents, 2007
The mineralocorticoid hormone aldosterone is essential in regulating the body’s salt and water balance. However, abnormal activation of the mineralocorticoid receptor (MR) by elevated levels of aldosterone and salt imbalance cause hypertension and other effects detrimental to the cardiovascular system. Thus, MR antagonists are expected to be beneficial
Marvin J Meyers, Xiao Hu
openaire   +1 more source

Aldosterone, Mineralocorticoid Receptor and the Metabolic Syndrome:Role of the Mineralocorticoid Receptor Antagonists

Current Vascular Pharmacology, 2012
Several lines of evidence suggest a detrimental effect of aldosterone excess on the development of metabolic alterations. Glucose metabolism derangements due to aldosterone action are frequently observed not only in patients with primary aldosteronism but also in patients with obesity. A contribution to the hyperaldosteronism observed in obese subjects
Ronconi, Vanessa, Turchi, Federica, Appolloni, Gloria, di Tizio, Valentina, BOSCARO, MARCO, Giacchetti, Gilberta   +5 more
openaire   +3 more sources

Emerging cardiovascular indications of mineralocorticoid receptor antagonists

Trends in Endocrinology & Metabolism, 2015
Mineralocorticoid receptor (MR) antagonism is a well-established treatment modality for patients with hypertension, heart failure, and left ventricular systolic dysfunction (LVSD) post-myocardial infarction (MI). There are emerging data showing potential benefits of MR antagonists in other cardiovascular conditions.
Parviz, Yasir, Iqbal, Javaid, Pitt, Bertram, Adlam, David, Al-Mohammad, Abdallah, Zannad, Faiez   +5 more
openaire   +2 more sources

Adverse Effects of Mineralocorticoid Receptor Antagonist Administration

Current Pharmaceutical Design, 2019
Background: Mineralocorticoid receptor antagonists consist of a class of drugs with pleiotropic beneficial effects in several cardiovascular diseases. However, physicians frequently overlook their use due to the adverse effects of such agents. Objectives: To determine the adverse effects of mineralocorticoid receptor antagonists and to suggest ...
Manolis S, Kallistratos, Andreas, Pittaras, Iakovos, Theodoulidis, Charris, Grassos, Leonidas E, Poulimenos, Athanasios J, Manolis   +5 more
openaire   +2 more sources

Mineralocorticoid receptor antagonists (MRAs)

2014
Abstract The final process in the renin–angiotensin–aldosterone system (RAAS) is the production of the mineralocorticoid aldosterone in the adrenal glands. Aldosterone has an important role in the pathophysiology of heart failure, and concentrations of aldosterone are 20-fold higher in patients with HF compared to normal individuals ...
Roy S. Gardner, Theresa A. McDonagh, Niki L. Walker   +2 more
openaire   +1 more source